BioMarin Preps For Vimizim Launch, Its Largest Yet
This article was originally published in The Pink Sheet Daily
The rare disease specialist is ramping up its commercial infrastructure and manufacturing capacity ahead of the launch of Vimizim, which could come in early 2014.
You may also be interested in...
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.
Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.
The approval of Cabometyx in combination with Opdivo as a first-line treatment for RCC will power substantial growth at Exelixis into 2022.